Protara Therapeutics, Inc. (TARA) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative therapies for cancer and rare diseases. The company has no approved products and generates no revenue. Its primary development programs include TARA-002 (an investigational cell therapy for non-muscle invasive bladder cancer [NMIBC] and lymphatic malformations [LMs]) and IV Choline Chloride (an investigational therapy for patients on parenteral support).
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(13.3) million | $(11.2) million | $(40.1) million | $(31.8) million |
| Diluted EPS | $(0.31) | $(0.50) | $(0.96) | $(1.74) |
| Operating Expenses | $14.8 million | $12.3 million | $45.5 million | $34.8 million |
| Investment Income | $1.5 million | $1.1 million | $4.9 million | $3.0 million |
| Cash & Equivalents | $12.6 million | $162.8 million | $12.6 million | $162.8 million |
| Marketable Securities | $121.1 million | $7.5 million | $121.1 million | $7.5 million |
| Total Liquidity | $133.6 million | $170.3 million | $133.6 million | $170.3 million |
Note: The company reclassified a significant portion of cash into marketable debt securities during the period. Total unrestricted cash and marketable securities were $133.6 million as of September 30, 2025.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses increased by $2.4 million (19.7%) in Q3 2025 compared to Q3 2024, and by $10.6 million (30.5%) on a year-to-date basis.
- R&D Expenses: Increased $1.5 million in Q3 and $7.3 million YTD. This was driven by startup costs for the IV Choline Chloride THRIVE-3 clinical trial and continued site expansion in the NMIBC ADVANCED-2 trial.
- G&A Expenses: Increased $0.9 million in Q3 and $3.3 million YTD, primarily due to higher personnel-related expenses and market development costs.
- Investment Activity: Net cash used in investing activities was $112.6 million for the nine months ended September 30, 2025, compared to $3.3 million in the prior year period. This reflects the purchase of $141.9 million in marketable debt securities.
- Financing Activity: Net cash provided by financing activities was $1.8 million YTD 2025, primarily from the partial exercise of the Underwriters' Option from the December 2024 public offering. This contrasts with $42.0 million in YTD 2024, which included proceeds from a private placement.
Outlook, Guidance, and Risks
- Liquidity: Management believes current financial resources are sufficient to satisfy estimated liquidity needs for at least twelve months from the date of filing. The company will need to raise additional capital to fully realize its plans.
- Clinical Milestones:
- TARA-002 (NMIBC): Interim data from the ADVANCED-2 trial showed a 100% complete response rate in a small cohort of BCG-Unresponsive patients. The company expects to present interim analysis from approximately 25 six-month evaluable patients in Cohort B in Q1 2026.
- IV Choline Chloride: The company intends to dose the first patient in the registrational Phase 3 THRIVE-3 trial by the end of 2025.
- TARA-002 (LMs): An interim update from the STARBORN-1 trial is expected in Q4 2025.
- Risks: The company faces risks related to the success of clinical trials, regulatory approvals, and the ability to secure additional financing. There are no current revenues, and the company expects to continue incurring significant operating losses.
Key Facts for Investor Verification
- Cash Burn Rate: Verify the sustainability of the $133.6 million liquidity position against the current burn rate of approximately $13.3 million per quarter.
- Capital Raise Needs: Confirm the timeline and strategy for future capital raises required to fund the Phase 3 THRIVE-3 trial and continued NMIBC development.
- Clinical Data Validation: Monitor the upcoming Q1 2026 interim data release for the ADVANCED-2 trial (Cohort B) to validate the 100% response rate observed in the smaller BCG-Unresponsive cohort.
- Regulatory Path: Track the FDA's feedback on the BCG-Naïve clinical program, with an update expected in Q4 2025.
- Investment Portfolio: Review the composition and maturity of the $121.1 million in marketable debt securities to assess liquidity flexibility.